Photosensitivity From Avapritinib: Pharamacovigilance Analysis.
Ajit Venkatakrishnan1, Brandon Chu2, Pushkar Aggarwal3
1University of Cincinnati, Cincinnati, OH, United States.
JMIR Dermatology
|October 30, 2024
Summary
A statistically significant link between Avapritinib and photosensitivity was found in real-world data. This tyrosine kinase inhibitor may increase the risk of sun sensitivity in patients, requiring careful consideration of benefits and risks.
Area of Science:
- Pharmacovigilance
- Oncology
- Dermatology
Background:
- Avapritinib is a tyrosine kinase inhibitor approved for certain conditions.
- Photosensitivity is a known side effect of some protein kinase inhibitors.
- Real-world data on Avapritinib-induced photosensitivity requires investigation.
Purpose of the Study:
- To determine if a statistically significant association exists between Avapritinib use and photosensitivity.
- To analyze real-world adverse event data for signals of photosensitivity.
- To review existing literature for reported cases of Avapritinib-induced photosensitivity.
Main Methods:
- Disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
- Data collection period: January 1, 2020, to December 31, 2021.
- Literature review for published case reports.
Main Results:
- A statistically significant signal for photosensitivity associated with Avapritinib was identified.
- The disproportionality analysis yielded a proportional reporting ratio of 11.0.
- One case report detailed photosensitivity in a patient on Avapritinib for 5 months.
Conclusions:
- A statistically significant association between Avapritinib and photosensitivity is established.
- Healthcare providers should remain vigilant for photosensitivity reactions in patients taking Avapritinib.
- Balancing the therapeutic benefits against the risk of photosensitivity is crucial when prescribing Avapritinib.
